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Abstract
Background: Antibiotic resistance is on the rise. A contributing factor to antibiotic resistance is the misuse of
antibiotics in hospitals. The current use of antibiotics in ICUs in Malawi is not well documented and there are no
national guidelines for the use of antibiotics in ICUs. The aim of the study was to describe the use of antibiotics in a
Malawian ICU.
Methods: A retrospective review of medical records of all admissions to the main ICU in Queen Elizabeth Central
Hospital in Blantyre, Malawi, between January 2017 and April 2019. Data were extracted from the ICU patient
register on clinical parameters on admission, diagnoses, demographics and antibiotics both prescribed and given
for all patients admitted to the ICU. Usage of antibiotics in the ICU and bacterial culture results from samples taken
in the ICU and in the peri-ICU period, (from 5 days before ICU admission to 5 days after ICU discharge), were
described.
Results: Six hundred-and-forty patients had data available on prescribed and received medications and were
included in the analyses. Of these, 577 (90.2%) were prescribed, and 522 (81.6%) received an antibiotic in ICU. The
most commonly used antibiotics were ceftriaxone, given to 470 (73.4%) of the patients and metronidazole to 354
(55.3%). Three-hundred-and-thirty-three (52.0%) of the patients received more than one type of antibiotic
concurrently – ceftriaxone and metronidazole was the most common combination, given to 317 patients. Forty five
patients (7.0%) were given different antibiotics sequentially. One-hundred-and-thirty-seven patients (21.4%) had a
blood culture done in the peri-ICU period, of which 70 (11.0% of the patients) were done in the ICU. Twenty-five
(18.3%) of the peri-ICU cultures were positive and eleven different types of bacteria were grown in the cultures, of
which 17.2% were sensitive to ceftriaxone.
Conclusion: We have found a substantial usage of antibiotics in an ICU in Malawi. Ceftriaxone, the last-line
antibiotic in the national treatment guidelines, is commonly used, and bacteria appear to show high levels of
resistance to it, although blood culture testing is infrequently used. Structured antibiotic stewardship programs may
be useful in all ICUs.
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Introduction
Antibiotic resistance is on the rise. Globally, the esti-
mated 700,000 people who die each year due to drug re-
sistant infections is projected to increase to 10 million a
year by 2050 [1]. The rate of production of new antibi-
otics is declining [2] and the UN states that resistance to
antibiotics is a global health threat requiring urgent at-
tention [3, 4].
A contributing factor to antibiotic resistance is the
misuse of antibiotics in hospitals [5–7]. A recent study
in Malawi found that one-third of bacteria grown in
blood cultures from hospitalized children were resistant
to Ceftriaxone, the most commonly used parenteral anti-
biotic in the hospital [8]. Resistance additionally results
in longer hospital stays for patients [9], increased costs
[10] and death [11].
A rational use of antibiotics is necessary for optimizing
patient outcomes [11]. Critically ill patients admitted to
Intensive Care Units (ICUs) are at greater risk of serious
morbidity and death if antibiotic therapy fails [11–13].
Malawi, a low-income country in Africa, has 25 ICU
beds for a population of 17 million people [14, 15]. The
current use of antibiotics in ICUs in Malawi is not well
documented and there are no national guidelines for the
use of antibiotics in ICUs. The aim of the study was to
describe the use of antibiotics in a Malawian ICU.
Methods
A retrospective review of medical records for all admis-
sions to the main ICU in Queen Elizabeth Central Hos-
pital in Blantyre, Malawi between January 2017 and
April 2019.
Study setting
Queen Elizabeth Central Hospital (QECH) is a large,
state-run hospital in Blantyre, Malawi with 1000 beds.
The hospital serves an immediate catchment population
of 1 million people and is a referral center for the south-
ern region of Malawi and the whole country. The main
ICU has four beds and admits patients from all wards
and all specialties in the hospital. The closed ICU is run
by the department of anesthesia and intensive care and
has continuous observation with a 1:1 nurse: patient ra-
tio, vital signs monitoring, oxygen supplied by cylinders,
electric suction, mechanical ventilation for the four beds,
and can deliver vasoactive infusions with syringe drivers.
Study population
All patients admitted to the ICU between January 2017
and April 2019. Patients who lacked data on prescribed
and received medications were excluded.
Data collection
Data for the study were extracted from the ICU patient
register. The register contains information on clinical
parameters at admission, diagnoses, demographics and
treatments both prescribed and given, (some patients
were prescribed a treatment by clinicians, but were not
given the treatment due to stock-outs or other reasons),
for all patients admitted to the ICU. Medication pre-
scriptions in the ICU are primarily done by the admit-
ting anesthetic clinical officer or anesthesiologist often
in consultation with other specialty physicians. The spe-
cialty team the patients belongs to at times reviews pre-
scriptions and can modify in agreement with the
anaesthetist in the ICU. Admission data were extracted
to a paper-based data collection tool from the patient
observation charts by the research team from January
2017 to November 2017, and by the nurses and clini-
cians in the ICU from December 2017 onwards. Data on
antibiotic treatments during the ICU period were added
to the register from patient treatment charts and blood
culture results were added to the register from the hos-
pital’s laboratory database, which is run by the neighbor-
ing research affiliate, the Malawi-Liverpool-Wellcome
Trust. Other types of cultures are not done in the hos-
pital. The laboratory uses bioMérieux BACT/ALERT 3D
for detecting microorganisms in blood. Routine standard
laboratory procedures were followed by qualified labora-
tory personnel and antibiotic sensitivity profiles inter-
preted according to British Society for antimicrobial
chemotherapy guidelines. Quality controls are performed
using known Public Health of England National Collec-
tion of Type Cultures bacterial reference strains and the
laboratory participates in external UK and USA based
quality assurance. The data were entered into the elec-
tronic register database using double-data-entering and
quality-checking by two staff members, and follow-up of
missing data by the ICU clerk. An anonymous extract of
the data was used for the study.
Data analysis
Descriptive data were summarized using proportions,
means, ranges, medians and interquartile ranges where
appropriate. The many diverse diagnoses were grouped
into eight categories, (serious infection, non-
communicable disease [e.g. cancer, anaemia, unspecified
tumours], trauma, bowel perforation or obstruction,
post-delivery or abortion care, acute respiratory disease,
pre-eclampsia/eclampsia, other/unknown), by the re-
searchers. The number of antibiotics given to each pa-
tient was recorded, and the usage of more than one
antibiotic was classed as concurrent or sequential. Con-
current use was a patient receiving two or more antibi-
otics at the same time. Sequential use was when the first
antibiotic was discontinued and subsequently a second
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antibiotic was commenced. Blood cultures were classi-
fied as being taken on the first day of admission to ICU,
taken during the ICU stay, taken during the peri-ICU
period – from 5 days before ICU admission to 5 days
after ICU discharge – or taken at any point during the
hospital stay. Blood culture results were classified as
positive or negative, and laboratory results stating, “no
significant growth (contaminant)”, were classified as
negative. Sensitivities to ceftriaxone of the cultured bac-
teria were noted. Data analysis was done with STATA
(Release 15, StataCorp, College Station, TX). Ethical
clearance was granted by the College of Medicine Re-
search and Ethics Committee (COMREC P.07/18/2433).
Results
There was a total of 740 admissions to the ICU during
the study period. Six hundred and forty patients had in-
formation on prescribed and received medications and
were included in the analysis. Their median age was 32
(IQR 22–45) and 326 (51.0%) were male. The surgical
and medical departments contributed more than half the
total number of participants with 213 (33.3%) and 131
(20.5%) respectively. Post-operative admissions
accounted for 352 (55.0%) of the participants. The par-
ticipants’ median length of stay in ICU was 2 days (IQR
1–4), 34.8% died in-ICU and a total of 45.5% died in-
hospital. (Table 1). The characteristics of the one hun-
dred patients who were excluded due to missing infor-
mation about medications did not differ substantially
from the included participants (Supplementary Table 1).
Antibiotic usage in ICU
Of the 640 patients, 522 (81.6%) were given an anti-
biotic. The modal number of antibiotics received was
two and 18 (2.8%) received four or five different antibi-
otics during their stay in ICU (Fig. 1). In total, 577 pa-
tients (90.2%) were prescribed an antibiotic and fifty-five
(9.5%) of the patients were prescribed but did not re-
ceive the antibiotic.
The most commonly used antibiotic was ceftriaxone,
given to 470 (73.4%) of the patients. The standard dose
of ceftriaxone to patients with normal renal function
was 2 g, given once a day - the frequency increased to
twice a day in patients with meningitis. Metronidazole
was given to 354 (55.3%) and meropenem to 30 (4.7%)
patients (Table 2). Three-hundred-and-thirty-three
(52.0%) of the participants received more than one type
of antibiotic concurrently – ceftriaxone and metronida-
zole was the most common combination, given to 317
patients (49.5%), 58 patients (9.1%) received a different
combination. Forty five patients (7.0%) were given differ-
ent antibiotics sequentially.
Blood cultures
In total, 192 (30.0% of the patients) had a blood culture
done during their stay in-hospital. One-hundred-and-
thirty seven- (21.4% of the patients) had a blood culture
done in the peri-ICU period, of these 70 were done in
the ICU (11.0% of the patients) and 9 (12.9% of the ICU
cultures) were done in ICU on the day of admission. Of
the eleven patients with positive ICU cultures, nine were
treated with ceftriaxone. In five of these, bacteria were
grown that were resistant to ceftriaxone. All the five
Table 1 Patient and Infection characteristics
Variable n (%)
N = 640
Male sex 326 (51.0%)




Obstetrics and Gynaecology 108 (16.9%)
Neurosurgery 105 (16.4%)
Peadiatrics 39 (6.1%)




Emergency department 137 (21.4%)
Ward 128 (20.0%)
Recovery room 3 (0.5%)
Other 20 (3.1%)
Diagnosis
Serious Infectionb 141 (22.0%)
Non-communicable diseasec 133 (20.8%)
Traumad 103 (16.1%)
Bowel perforation or obstructione 98 (15.3%)
Post-delivery or abortion care 43 (6.7%)
Acute respiratory diseasef 35 (5.5%)
Pre-eclampsia/eclampsia 16 (2.5%)
Other/ Unknown 71 (11.1%)
Length of stay in days Median (IQR) 2 (1–4)
Duration of care with antibiotics in the ICU Median (IQR) 2 (1–4)
ICU mortality 223 (34.8%)
Length of stay for those who died Median (IQR) 2 (1–5)
Hospital Mortality 291 (45.5%)
a Orthopedics, Burns and Oncology
bIncluding Meningitis, Malaria, Endometritis, Pneumonia, sepsis/septic shock
and Tuberculosis
c Cancer, Anaemia, unspecified tumours
dIncluding Head injury and Burns
eincluding Typhoid perforation
f includes Asthma and Pulmonary Oedema
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Fig. 1 Number of antibiotics given to the patients in ICU
Table 2 Antibiotics prescribed and given in the ICU
Antibiotic Number of courses
prescribed N = 1024
Number of courses
given N = 933
Proportion of all
antibiotic courses
given N = 933
Proportion of patients
who were given the
antibiotic N = 640
Ceftriaxone 520 470 50.4% 73.4%
Metronidazole 378 354 38.0% 55.3%
Meropenem 43 30 3.2% 4.7%
Ciprofloxacin 17 17 1.8% 2.6%
Cotrimoxazole 15 12 1.3% 1.9%
Piperacillin Tazobactam 13 13 1.4% 2.0%
Gentamycin 13 13 1.4% 2.0%
Doxycycline 4 4 0.4% 0.6%
Amoxicillin Clavulanate 3 3 0.3% 0.5%
Benzyl penicillin 3 3 0.3% 0.5%
Azithromycin 3 3 0.3% 0.5%
Flucoxacillin 2 2 0.2% 0.3%
Amikacin 2 2 0.2% 0.3%
Erythromycin 2 2 0.2% 0.3%
Amoxicillin 1 0 0.0% 0.0%
Ampicillin 1 1 0.1% 0.2%
Ceftazidime 1 1 0.1% 0.2%
Chloramphenicol 1 1 0.1% 0.2%
Clindamycin 1 1 0.1% 0.2%
Cloxacillin 1 1 0.1% 0.2%
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patients received ceftriaxone before the blood culture
was taken and no patient received ceftriaxone after re-
sistance was found.
Of the 137 peri-ICU cultures done, 25 (18.3%) were
positive, twenty three (16.8%) had a missing result, and
89 (65.0%) were negative. Of the 70 blood cultures taken
in ICU, 11 (15.7%) tested positive. Among the patients
who had a blood culture done in the peri-ICU period,
43.8% died while among those who did not have a blood
culture done, 32.4% died.
Twenty-nine bacteria were grown in the 25 positive
peri-ICU blood cultures and can be seen in Table 3. Five
bacteria (17.2%) were sensitive to ceftriaxone, (three of the
Staphylococcus aureus, one of the Escherichia coli and the
Salmonella typhi). Eight were not tested, and the
remaining 16 were resistant to ceftriaxone, (five of the
Klebsiella pnemoniae, five of the Acinetobacter baumanii,
three of the Escherichia coli, two of Alpha-haemolytic
streptococcus, and one of the Proteus mirabilis).
Discussion
Among a population of patients in an ICU in Malawi,
81.6% received antibiotics during their ICU stay and
more than half received two or more antibiotics. An
additional 9.5% of patients were prescribed but did not
receive an antibiotic – possibly due to medication stock-
outs.
A frequent use of antibiotics in ICUs has been re-
ported elsewhere [11, 16, 17]. In South Africa and
Ghana, 75 and 71% of ICU patients were given antibi-
otics respectively [17, 18]. In our study we found ceftri-
axone was the most commonly used antibiotic. This use
of ceftriaxone is likely to be guideline triggered as the
Malawi standard treatment guidelines (supplementary
file 1) recommends that ceftriaxone be given as the ini-
tial course before a blood culture is done [19]. Cephalo-
sporins and other broad spectrum antibiotics are also
commonly used in ICUs in other countries [16, 20].
We have found a substantial use of more than one anti-
biotic concurrently. Some of this is likely to be rational –
for example the most common combination was ceftriax-
one and metronidazole which, with their differing spectrum
of action are a rational choice for diseases such as abdom-
inal sepsis. Irrational concurrent use may also have been
prevalent but is difficult to judge due to the lack of available
detailed clinical information. Irrational use of antibiotics
has been reported to be a contributing factor to poor out-
comes such as prolonged length of stay and death in ICU
[21] and increases costs [22]. Indeed, efforts through anti-
biotic stewardship programs are being put in place to help
combat the problem of irrational antibiotic use in health-
care both in Malawi and other countries [13, 23–26]. Dur-
ing this study period, there was no evidence of such
programs in the ICU and we are not aware of programs
tackling antibiotic use specifically in ICUs in Malawi.
While antibiotics in ICU are used for many types and
sources of infections, blood cultures may be used to direct
the appropriate choice of antibiotic [11, 27, 28]. Our find-
ings of infrequent testing of blood cultures, the low yield of
positive results and the predominant use of broad-
spectrum antibiotics suggest that most antibiotics were be-
ing used empirically for patients with suspected infection,
without the guidance of blood cultures. Despite the sparse
positive blood culture results, we have found antibiotic re-
sistance in the ICU. These findings are similar to other
studies done in other ICUs in Africa [13, 29]. Resistance to
ceftriaxone poses a major threat to the critically ill patients
as other potent antibiotics for critically ill patients can be
scarce in Malawi. The sparse use of blood cultures in the
ICU, could be attributed to cost concerns, a lack of speci-
men collection bottles in the unit, a lack of awareness
among clinicians, the fact that antibiotics are often initiated
before admission to ICU so cultures may be seen as less
clinically relevant, or poor communication with referring
units about previous cultures and the need for repeat tests
in the ICU.
Table 3 Bacteria grown in the cultures
Bacteria Bacteria grown in the Peri-ICU positive cultures N = 29 ICU cultures with positive growth of bacteria N = 13
Klebsiella pnemoniae 5 2
Acinetobacter baumanii 5 4
Escherichia coli 4 0
Alpha-haemolytic streptococcus 4 2
Enterococcus faecalis 3 1
Group D streptococcus 2 2
Staphylococcus aureus 2 0
Proteus mirabilis 1 0
Salmonella typhi 1 0
Streptococcus pyogenes 1 0
Pseudomonas aeruginosa 1 1
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The higher mortality seen in patients who had blood
cultures taken may seem surprising. However, it is likely
explained by local practices of taking blood cultures in
more severely unwell patients, or in those who are not
responding to treatment.
Our study is the first of its kind to look at the anti-
biotic usage in an ICU in Malawi, and links over 2 years
of data from the ICU register to the laboratory database.
Limitations of our single-center study include the lack of
available medication data for some ICU patients and the
limited available clinical information to understand the
rationality of the antibiotic usage.
A structured antibiotic stewardship program focus-
ing on what is feasible may be useful in ICUs in
Malawi and other low-resource settings. Patterns of
infectious diseases in the unit, current treatments and
outcomes for the patients should be mapped out.
Local susceptibility patterns should be studied and
used to develop guidelines for initial antibiotic ther-
apy for patients with suspected bacterial infections
depending on diagnosis and clinical condition. Pa-
tients’ previous investigations, blood culture results
and antibiotic treatments should be communicated
between hospital departments. Where possible, blood
cultures should be done on arrival to ICU, when a
bacterial infection is suspected, and when a patient is
not responding to treatment and should include sen-
sitivity testing. Antibiotic therapy should be reviewed
daily, and clinical and laboratory information used for
decisions about whether to continue, modify, or dis-
continue therapy. Multidisciplinary teams should be
involved in decisions, including ICU clinicians, nurses,
specialty doctors and microbiologists [26].
Conclusion
We have found a substantial usage of antibiotics in
an Intensive Care Unit in Malawi. Ceftriaxone, the
last-line antibiotic in the national treatment guide-
lines, is commonly used, and bacteria appear to
show high levels of resistance to it, although blood
culture testing is infrequently used. Structured anti-
biotic stewardship program may be useful in all
ICUs.
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